At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
In Brief
A clinical study evaluating Sevelamer Carbonate and Placebo for Secondary Hyperparathyroidism. Completed, enrolled 18 participants across 1 site.
Detailed Summary
FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be lowered in patients with kidney disease by preventing them from absorbing phosphorus from food. This study is designed to see what happens to levels of FGF-23 in the blood when patients with chronic kidney disease take medications to prevent phosphorus absorption. Since high levels of FGF-23 have been linked with increased rates of death in patients with advanced kidney disease, controlling the levels may, in the future, be a way to decrease heart disease in patients with kidney disease.
Study Details
Timeline
Interventions
Daily renvela (800 mg tid with meals) x 12 weeks
1 inert tablet tid x 12 weeks